Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19966411 | 0.81 | BCDIN3D (0.40) | PDE2AKMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL18343699 | 0.74 | PDE2A (0.49) | PDE2AKMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL29950508 | 0.74 | PDE2A (0.43) | PDE2AKMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL27028464 | 0.74 | PDE2A (0.43) | PDE2AKMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL17889388 | 0.73 | PDE2A (0.47) | PDE2AKMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL55774 | 0.72 | PDE2A (0.64) | PDE2AKMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL4918794 | 0.70 | ALDH1A1 (0.44) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL24954062 | 0.69 | PDE2A (0.47) | PDE2AKMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL31106964 | 0.69 | PDE2A (0.47) | PDE2AKMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL16517280 | 0.68 | PDE2A (0.54) | PDE2AKMT2AKDM4EMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510033-B1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-11-24 | — | — | EP | disclosed |
| US-20210101902-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-04-08 | — | — | US | disclosed |
| US-10954233-B2 | Compounds and compositions as inhibitors of endosomal toll-like receptors | NOVARTIS AG (CH) | 2021-03-23 | — | — | US | disclosed |
| US-20190211009-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210101902-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | PDE2A 2973/4885KMT2A 3726/4885KDM4E 1751/4885 |
| US-20190211009-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | PDE2A 2973/4885KMT2A 3726/4885KDM4E 1751/4885 |
| US-10954233-B2 | Compounds and compositions as inhibitors of endosomal toll-like receptors | TLR3, TLR1, TLR4 | PDE2A 2973/4885KMT2A 3726/4885KDM4E 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.